Resistant bacterial strains are becoming an increasing challenge, which needs to be addressed immediately. This is a great opportunity for the pharmaceutical industry. There is a growing need to develop novel defense mechanisms and novel strategies to treat bacterial infections.  To successfully tackle antibacterial resistance, novel targets are only part of the equation - challenges which also need to be addressed include new developments with gram-negative bacteria, predicting toxicology, selectivity, resistance, permeability and pharmacokinetics of new leads, as well as creating new models for optimization of leads and compounds. This conference is designed to bring together top level scientists from the academic, pharmaceutical and biotech fields to define and refine the path of developing novel antibacterials. Don’t miss the opportunity to discuss the current challenges and newest ideas and results and to present your own research and concepts in form of a poster to an international assembly of experts at this successful event.

Distinguished Faculty:

Development of Methionyl tRNA Synthetase Inhibitors against S. aureus and C. difficile infections
Urs Ochsner, Ph.D., Principle Scientist, Head of Microbiology, Replidyne, Inc.

Anti-MRSA Protein Synthesis Inhibitors: New and Old
Mike F. Gordeev, Ph.D., Chief Scientific Officer, MicuRx Pharmaceuticals, Inc.

Lantibiotics - A New Class of Antibiotics for Treatment of Nosocomial Infections
Michael Dawson, Ph.D., Chief Scientific Officer, R&D, Novacta  Biosystems, Limited

The Gram – Negative Challenge – the Effect of Novel Beta-Lactams
Jutta Heim, Chief Scientific Officer, Research, Basilea Pharmaceutica International, AG

Discovery of the Pyrimidine Series of Antibacterial Agents through Structure-Guided Lead
Discovery and Optimization
John Finn, Ph.D, Chief Scientific Officer, Trius Therapeutics

Title TBA
Graham Johnson, Chief Research Officer, Rib-X Pharmaceuticals

Bacterial Quorum Sensing: A New Target for Anti-Virulence Immunotherapy
Gunnar F. Kaufmann, Ph.D., Assistant Professor, The Kim D. Janda Laboratory, Department of Chemistry, The Scripps Research Institute

Title TBA
Lynn Silver, Ph.D., Silver Consulting

The Story of PZ-601 and Protez P – a Case Study
Luigi Xerri, Ph.D., Co-Founder, Chief Scientific Officer, Protez Pharmaceuticals, Inc.